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New Therapy Update
Abstract: Celiprolol is a β-blocker with a unique pharmacologic profile: it 
is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this 
combination of effects, celiprolol may be better described as a selective adr-
enoreceptor modulator. It has antihypertensive and antianginal properties and 
is indicated for those uses in various countries around the world. In the United 
States, however, the proposed indication for this drug will be for the treatment 
of vascular type Ehlers–Danlos syndrome, a rare connective tissue disorder 
characterized by fragile arterial structure and an increased risk of life-threat-
ening vascular complications. By reducing heart rate and pulsatile pressure, 
celiprolol may reduce the mechanical stress on collagen fibers within the 
arterial wall and be of benefit in patients with vascular type Ehlers–Danlos 
syndrome. The largest investigation of celiprolol in vascular Ehlers–Danlos 
syndrome was prematurely terminated due to significant benefit with celip-
rolol in reducing arterial events in patients with this condition. Celiprolol, 
therefore, represents a β-blocker that is unique from others in its class in both 
its pharmacology and clinical applications.
Key Words: celiprolol, Ehlers–Danlos, β-blockers, vascular Ehlers–Danlos 
syndrome, Ehlers–Danlos syndrome, Ehlers–Danlos syndrome type IV
(Cardiology in Review 2017;25: 247–253)
β-Adrenoceptor–blocking agents (also known as β1-adrenoceptor antagonists or β-blockers) are used to treat a variety of disorders 
such as arterial hypertension, systemic hypertension, angina, coronary 
heart disease, arrhythmias, hypertrophic cardiomyopathy, mitral valve 
prolapse, migraine, and glaucoma.1–3 The pharmacological classifica-
tion of these agents is based on their affinity, β1-selectivity, partial 
agonist activity, effects on other adrenergic receptors, and physico-
chemical properties.1 For some conditions, the efficacy of the various 
β1-adrenoceptor antagonists is similar, whereas in other conditions, 
only certain subgroups have demonstrated therapeutic benefits. In the 
United States, there are currently 17 β-adrenoceptor antagonists avail-
able for the treatment of cardiovascular and other disorders, although 
globally there are over 30 available for clinical use (Figure 1).4 Celipro-
lol (3-[3-acetyl-4-(3-t-butylamino-2- hydroxypropoxy)phenyl]-2,1-di-
ethylurea hydrochloride; Figure 2) was developed as a third-generation 
β1-adrenoceptor antagonist with partial β2 agonist activity and a 
unique pharmacological profile.5 Like β blockers, it demonstrates 
antihypertensive and antianginal activity; however, it lacks the typi-
cal side effects of the class, such as bronchoconstriction, depression 
of left ventricular function, and peripheral vasoconstriction.5 This is 
likely a result of its β2 agonist activity.2,6–9 Given this unique combina-
tion of pharmacologic effects, celiprolol is perhaps more accurately 
described as a selective adrenoceptor modulator (SAM). Furthermore, 
celiprolol’s ability to stimulate β2-receptors, influence vascular tone, 
and directly affect smooth muscle suggests its potential usefulness in 
patients with cardiovascular disease and concomitant lung disease.2,3,8 
Recently, the unique properties of celiprolol have inspired investiga-
tion into its use in a rare connective tissue disorder—Ehlers–Danlos 
syndrome, vascular type (vEDS; formerly known as EDS type IV).
There are 6 major types of EDS, each defined according to signs 
and symptoms and thought to involve a unique connective tissue defect 
(Table 1).10,11 vEDS is an autosomal dominant inherited connective tissue 
disorder (100% phenotypic penetrance) caused by structural defects of 
the pro α1 (III) chain of collagen type III (COL3A1) gene.12,13 Mutations 
in the COL3A1 gene result in decreased thermal stability and proteolytic 
processing irregularities, which subsequently lead to procollagen degra-
dation.13 Complications of vEDS include life-threatening arterial dissec-
tions and ruptures, vascular aneurysms, intestinal ruptures, and uterine 
ruptures.14 The average life span of patients with vEDS is approximately 
50 years of age, with manifestation of the disorder often evident by 20 
years of age.15,16 vEDS is suspected when a combination of clinical find-
ings is present. The Villefranche criteria provide guidance on clinical 
diagnosis (Table 2).14,17 The diagnosis is confirmed by the identification 
of a pathogenic mutation in COL3A1 gene or the appearance of abnor-
mal type III procollagen in cultured fibroblasts in patients with clinical 
features of vEDS.15 Currently, there are no Food and Drug Administra-
tion (FDA)–approved therapies for vEDS.18 Celiprolol was investigated 
for the treatment of vEDS because of the observed effects of reduced 
heart rate, mean, and pulsatile pressures in animals and in patients with 
hypertension and with potentially decreased continuous and pulsatile 
mechanical stress on collagen fibers within the arterial wall.19 On the 
basis of these data and on the fragile connective tissues associated with 
vEDS, celiprolol was investigated as a preventive therapy for the life-
threatening risks, specifically arterial dissections and ruptures and intes-
tinal and uterine ruptures associated with vEDS.
PHARMACOKINETIC PROPERTIES OF CELIPROLOL
As a whole, β1-adrenoceptor antagonists have similar therapeu-
tic effects; however, their pharmacokinetic properties differ.19 This is 
attributed to the distinct aromatic ring structure of these compounds, 
which results in differences in absorption, metabolism, first-pass hepatic 
metabolism, lipid solubility, protein binding, and renal clearance among 
the drugs. Specifically, configuration of the asymmetric β-carbon of 
the side chain determines activation or blockade effect.20 Celiprolol’s 
aromatic ring structure (benzene) is similar to other β1-adrenoceptor 
antagonists and is most closely related to acebutolol (Figure 2).21,22
Absorption
β1-Adrenoceptor antagonists are either considered lipophilic 
or hydrophilic. Celiprolol is a hydrophilic agent, freely soluble in 
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water.23 Most β1-adrenoceptor antagonists (except atenolol) are 
absorbed in the small intestine.1 Mean peak plasma concentrations 
after oral doses of 100–600 mg of celiprolol range from 300 to 3000 
µg/L.23,24 The bioavailability of celiprolol is dose-dependent: 30% at 
100 mg and 70% over the range 300–400 mg.24,25 Food may impair 
this bioavailability; however, the effect is not clinically relevant with 
long-term therapy.23 Grapefruit juice and orange juice, both inhibi-
tors of the organic anion–transporting polypeptide 1A2 (OATP1A2), 
have been shown to cause a significant decrease in the oral absorp-
tion of celiprolol.26 Although the clinical relevance of this interaction 
has not been fully assessed, studies have suggested that the effects of 
celiprolol on blood pressure and heart rate are not affected. Neverthe-
less, the marked reduction in celiprolol bioavailability in the presence 
of grapefruit or orange juice suggests that this interaction may be of 
clinical significance in some patients.26,27 In addition, concomitant 
administration of drugs such as chlorthalidone, hydrochlorothiazide, 
theophylline, or digoxin may have an effect on its bioavailability.23 
As a class, β1-adrenoceptor antagonists are known to interact with 
several drugs, particularly with agents that affect cardiovascular 
function. A list of select drug interactions with celiprolol is found 
in Table 3.2,25–28
Distribution
Distribution of β1-adrenoceptor antagonists occurs rapidly 
from the blood to other tissues.29 The distribution of celiprolol has 
been studied in animals and humans. Celiprolol was found to be a 
water-soluble substance that is widely distributed in all tissues, with 
the exception of the brain, after absorption.24 This is likely due to 
its hydrophilic properties.23,25,29 In vitro studies indicate that the rate 
of diffusion across the human placenta is 3–4 times lower than that 
of comparative β-blockers (propranolol, timolol, and labetalol) with 
approximately 25% plasma protein binding (Table 4).24 It is unclear 
whether this translates to a lower risk of fetal complications with 
celiprolol.
Metabolism
Celiprolol is minimally metabolized, with only a very low per-
centage of a dose being excreted.8 Similar to other β1-adrenoceptor 
antagonists, celiprolol displays first-pass metabolism. However, 
the concentration of celiprolol is greatly reduced before it reaches 
the systemic circulation. A small study in healthy volunteers dem-
onstrated no drug accumulation with chronic dosing over a 7-day 
period.8
Excretion
According to their pharmacokinetic properties, β1-
adrenoceptor drugs are divided into 2 categories: those eliminated 
via hepatic metabolism and those eliminated (unchanged) via the 
kidney.30 The pharmacokinetics of celiprolol have been studied in 
animals and patients with primary hypertension and chronic stable 
angina pectoris.24 Investigations have found that celiprolol is mini-
mally metabolized and excreted unchanged via the urine and feces, 
with a half-life of approximately 4–5 hours (10–15% observed dose 
excreted in the urine).23,24 One study also reports the possible urinary 
excretion of a celiprolol metabolite.7
A summary of celiprolol’s pharmacokinetic properties is 
found in Table 4.8,23
PHARMACODYNAMIC PROPERTIES OF CELIPROLOL
Celiprolol was developed as a third-generation β-adrenoceptor 
antagonist with selective β1-antagonist, partial β2-agonist, and mild 
α2-antagonist actions. The α2 antagonism is weak and ineffective 
in blocking the effects of the α2 agonist clonidine. The α2 agonist 
effects of celiprolol are, therefore, believed to contribute little to its 
overall pharmacologic effect.23 Its blockade of β1-adrenoreceptors 
reduces sympathoadrenal stimulation of the heart during physiologi-
cal stress.23 In addition, celiprolol’s blockade of β1-adrenoreceptors 
reduces heart rate (negative chronotropic effect) in the sinoatrial node 
and decreases cardiac contractility (negative inotropic effect) in the 
myocardium.23 Furthermore, studies indicate that celiprolol improves 
vasodilation through β2 agonism and may also act on β3 receptors as 
evidenced by a 2013 study of porcine coronary arteries, which dem-
onstrated that celiprolol exerts β3-adrenoceptor agonistic activity with 
resulting vasorelaxation.2,5,6 In addition, celiprolol may induce coro-
nary vasodilation due to stimulation of the release of nitric oxide.31 As 
a result of this activity profile, celiprolol may offer advantages over 
other β-adrenergic antagonists due to its bronchosparing properties, 
mild lipid effects, and minor cardiac conduction effects.2











FIGURE 2. Celiprolol chemical structure.
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Cardiovascular Effects
Studies support the idea that celiprolol reduces arteriolar 
resistance and improves blood flow without depressing cardiac func-
tion.23 In healthy adults, a single 400-mg oral dose reduced stand-
ing diastolic blood pressure by approximately 10% with no change 
in systolic blood pressure.32 In patients with hypertension, celip-
rolol moderated the positive chronotropic effects of sympathetic 
arousal, did not depress resting cardiac output, and reduced resting 
total peripheral resistance.23 Regarding celiprolol’s effect on cardiac 
conduction, in vivo animal studies demonstrated that treatment did 
not accelerate the ventricular rate during electrically induced atrial 
fibrillation despite stimulation of cardiac β2-adrenoceptors.33 Fur-
thermore, celiprolol had no membrane stabilizing or local anesthetic 
activity.25,33 In a small study of patients with stable atrial fibrillation, 
the normalized maximum rate of left ventricular pressure reduction 
immediately after systole (dP/dt
ip
) increased by 24%, and the left 
ventricular relaxation time constant declined by 20% after celipro-
lol administration.23 In addition, Vyssoulis et al34 found, in patients 
with left ventricular hypertrophy, that celiprolol lowered blood pres-
sure to normal levels and reduced left ventricular size estimated from 
TABLE 1. EDS Types
EDS Type Distinguishing Characteristics Estimated Frequency
Hypermobile Chronic pain and joint hypermobility that may lead to subluxations and dislocations. 1 in 10,000 to 15,000 people
Classical Skin hyperextensibility (stretchy) and joint hypermobility. Skin is smooth, velvety, 
and fragile.
1 in 20,000 to 40,000 people
Vascular Most serious of all the EDS types due to possibility of arterial or organ rupture. 
Skin is usually thin and translucent, which is most apparent over the chest and 
abdomen.
1 in 90,000 to 250,000 people
Kyphoscoliosis Joint laxity and weak muscle tone at birth with progressing scoliosis. About 60 cases reported worldwide.
Arthrochalasia Congenital hip dislocation often associated with severe generalized joint 
hypermobility with recurrent subluxations.
About 30 cases reported worldwide.
Dermatosparaxis Severe skin fragility with substantial bruising. Skin is soft, doughy, and sagging. About a dozen cases reported worldwide.
EDS indicates Ehlers–Danlos syndrome.
Data adapted from National Institutes of Health10 and Ehlers Danlos Society.11
TABLE 2. vEDS Criteria
Major diagnostic criteria
• Arterial aneurysms, dissection, or rupture
• Intestinal rupture
• Uterine rupture during pregnancy
• Family history of vEDS
Minor diagnostic criteria
• Thin, translucent skin
• Characteristic facial appearance (thin vermilion of the lips, 
micrognathia, narrow nose, and prominent eyes)
• Acrogeria (an aged appearance to the extremities, particularly the 
hands)
• Carotid–cavernous sinus arteriovenous fistula
• Hypermobility of small joints
• Tendon/muscle rupture
• Early-onset varicose veins
• Pneumothorax/hemopneumothorax
• Easy bruising
• Chronic joint subluxations/dislocations
• Congenital dislocation of the hips
• Talipes equinovarus (clubfoot)
• Gingival recession
vEDS indicates vascular Ehlers–Danlos syndrome.
Data adapted from Byers and Holbrook,12 Pepin et al,15 and Oderich et al.16
TABLE 3. Celiprolol Drug Interactions
Agent Nature of Interaction
Chlorthalidone and 
hydrochlorothiazide




In combination with β adrenergic 
antagonists, have additive effects on 
cardiac conductive system
Clonidine β-Adrenergic antagonists may 
exacerbate the rebound hypertension, 
which can follow withdrawal of 
clonidine
Antidiabetic agents In combination with β adrenergic 
antagonists, may intensify blood 
sugar–lowering effects of insulin 
and antidiabetic drugs and may 




May decrease the hypotensive effects of 
β-adrenergic antagonists
Orange juice Reduces the bioavailability of celiprolol
Grapefruit juice Reduces celiprolol plasma 
concentrations
Itraconazole Almost doubles celiprolol plasma 
concentrations, likely due to 
increased absorption
Rifampin/rifampicin Reduces celiprolol plasma 
concentrations, likely due to reduced 
absorption
Sympathomimetic agents Counteract the effects of β-adrenergic 
antagonists
Concomitant use of other 
antihypertensive agents or 
tricyclic antidepressants, 
barbiturates, or phenothiazines
Potentiate the antihypertensive effects 
of β adrenergic antagonists
Data adapted from Riddell et al25 and Lilja et al.26–28
TABLE 4.  Pharmacokinetic Properties of Celiprolol






300–3000 μg/L after oral doses of 100–600 mg
Metabolism Minimal
Excretion 10–15% of oral dose excreted in urine, remainder in 
feces
Data adapted from Caruso et al8 and Smith and Wolf.24
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end-systolic and diastolic diameters, interventricular septal thick-
ness, and posterior wall thickness at end diastole and end systole.
Small studies with celiprolol in patients with heart failure have 
shown variable results. In 1 study of 16 patients with reduced left 
ventricular ejection fraction (LVEF), 3 months of celiprolol therapy 
showed hemodynamic benefits and improved LVEF in patients with 
nonischemic cardiomyopathy, but the benefits in those with ischemic 
cardiomyopathy were mixed.35 A larger study of 132 patients with 
reduced LVEF showed no difference between celiprolol and placebo 
in the primary end point of change in functional status (measured 
by the Goldman score) after 1 year of treatment.36 Some of the sec-
ondary efficacy measures showed an advantage with celiprolol (heart 
rate was reduced more and DiBianco heart failure score, which is 
a composite of exertional and decubitus dyspnea, asthenia, and leg 
edema was reduced more), but other efficacy measures showed no 
significant differences compared to placebo (LVEF, end-diastolic 
diameter, fractional shortening, and exercise duration).36 In aggre-
gate, although these small trials did not show consistent efficacy with 
celiprolol for treating heart failure, they did suggest that the drug was 
safe in this population.
Respiratory Effects
The effects of celiprolol on the respiratory function of healthy 
patients and asthmatic patients have been studied.36 Although respi-
ratory function in patients with asthma was not changed with single 
doses of celiprolol (200 or 400 mg), bronchospasm and asthma have 
been reported in nonasthmatic patients with ischemic heart disease 
and hypertension being treated with celiprolol.23,37,38 Monitoring for 
respiratory symptoms is, therefore, still recommended with the use 
of celiprolol in both asthmatic and nonasthmatic patients.38
Metabolic Effects
Similar to α-adrenoceptor antagonists, but unlike many other 
β1-adrenoceptor antagonists, celiprolol has no harmful effects on 
lipid and lipoprotein profiles but may have mild beneficial effects.39 
In a study of 100 patients with hypertension, celiprolol 200 mg once 
daily reduced low-density lipoprotein cholesterol (LDL-C) levels in 
hyperlipidemic patients (baseline LDL-C >160 mg/dL) by 16.9% and 
total cholesterol by 12.8%. No significant changes were observed in 
patients with baseline LDL-C levels lower than 160 mg/dL.39
In a small placebo-controlled, crossover study, celiprolol 100–
400 mg once daily did not induce significant changes in glomerular 
filtration rate, renal plasma blood flow, plasma renin activity, filtra-
tion fraction, serum creatinine, aldosterone, or urinary enzymes.40
CLINICAL TRIALS
Four trials demonstrated the role of celiprolol in improv-
ing hypertension and vascular elasticity. In 1988, Donaldson et al41 
evaluated the hemodynamic effects of celiprolol in a small group 
(n = 10) of patients diagnosed with ischemic heart disease. Cardiac 
catheterization was performed, and left ventricular pressure and aor-
tic pressure were recorded for 30 minutes post celiprolol treatment 
(intravenous infusion of 10 mg over 5 minutes). The measurements 
FIGURE 3. Kaplan–Meier curves of event-free survival in 53 patients with vascular Ehlers–Danlos syndrome. Primary end point 
(A). Primary and secondary endpoints (B). Reprinted with permission from the study by Ong et al.43
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were taken at rest, in sinus rhythm, and during atrial pacing at a rate 
of 100 bpm. Results of the study demonstrated that celiprolol exerted 
a vasodilatory effect without depressing cardiac function.41
A randomized, double-blind study was conducted in 2 cen-
ters over 9 months to understand the pathogenesis of the vascular 
lesions of vEDS. Ninety-eight patients with essential hypertension 
were treated with either 200-mg celiprolol or 10-mg enalapril.19 The 
efficacy was similar in both groups and indicated that the decrease in 
carotid artery internal diameter was significantly related to the reduc-
tion in pulse pressure rather than mean blood pressure.19
Roman et al42 utilized duplex echo Doppler techniques to 
determine the site of celiprolol’s vasodilating effect. Thirty-five 
hypertensive patients were treated with increasing doses of celipro-
lol, 200 and 400 mg, over 15 days. Duplex echo Doppler was used 
to measure forearm (brachial artery) arterial and arteriolar vasodila-
tion, before and during each celiprolol dose period. Celiprolol signif-
icantly (P < 0.05) increased brachial artery diameter and blood flow 
velocity compared to baseline. Statistically significant (P < 0.05) 
changes were also seen in forearm vascular measures: resistance 
decreased and compliance increased in response to celiprolol. These 
changes, except for blood flow velocity, occurred in a dose-depen-
dent manner.42
These trials formed the backdrop for a study of celiprolol 
in vEDS, a condition in which reduction of arterial wall stress and 
increased vascular elasticity would likely be beneficial.
In 2010, Ong et al43 demonstrated the reduction of arterial 
and organ complications in patients with vEDS after treatment 
with celiprolol. The Beta-Blockers in Ehlers-Danlos Syndrome 
(BBEST) study was a prospective, multicenter, randomized, open 
trial with blinded assessment of clinical events that evaluated 
53 patients who received either celiprolol or no treatment over 
a planned 5 years. The inclusion/exclusion criteria for this study 
were adapted from the Villefranche diagnostic criteria as shown 
in Table 2.43 Patients treated with celiprolol demonstrated a reduc-
tion in arterial events 3-fold greater than untreated patients (Fig-
ures 3 and 4).43 These results were achieved without significant 
changes in heart rate or blood pressure; the reduction in events was 
statistically significantly different from controls in the subset of 
vEDS patients with COL3A1 mutations.43,44 In addition, celiprolol 
demonstrated mild vasodilating effects in the hypertensive vEDS 
patients.42
ADVERSE EFFECTS
Pooled data from clinical trials of patients with primary 
hypertension and/or angina pectoris reported no difference in 
adverse events between celiprolol and placebo (Figure 5).3 Addi-
tional analyses have found celiprolol to not induce clinically sig-
nificant bradycardia compared to propranolol and to produce less 
dizziness, fatigue, and tiredness compared to atenolol—signifying 
an advantageous tolerability profile.23 Nonetheless, as with other 
FIGURE 4. Kaplan–Meier curves of event-free survival in 33 patients with vascular Ehlers–Danlos syndrome with positive 
COL3A1 mutation. Primary end point (A). Primary and secondary end points (B). Reprinted with permission from the study by 
Ong et al.43
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β-blockers, celiprolol should not be used in patients with cardio-
genic shock, decompensated heart failure, sick sinus syndrome, 
second- or third-degree heart block, or severe bradycardia.45 Celip-
rolol, unlike other β-blockers, may relax bronchial smooth muscle, 
rendering it theoretically safe for use in patients with pulmonary 
disease.45 In fact, several studies have shown celiprolol to not 
significantly affect respiratory function in patients with chronic 
obstructive lung disease46,47 or asthma.48,49 However, there have 
been reports of asthma and bronchospasm occurring in patients 
receiving celiprolol23,38 and a case of hypersensitivity pneumonitis 
occurring with celiprolol, which recurred upon rechallenge of the 
drug.50 Therefore, caution should still be exercised in patients with 
lung disease who are taking celiprolol, and monitoring for respira-
tory symptoms is still recommended even in patients without lung 
disease.38
USE IN VASCULAR EHLERS–DANLOS SYNDROME
Celiprolol is approved in many countries for the treatment of 
cardiovascular disorders; however, it is not yet approved in the United 
States for any indication. In 2015, the FDA granted celiprolol orphan 
drug status for the treatment of vEDS.51
Due to mutations in COL3A1 and abnormal vascular smooth 
muscle cell signaling, patients with vEDS have high carotid wall 
stress (steady or pulsatile) and are at high risk for arterial dissec-
tion and rupture.52 A reduction in the amplitude of carotid wall 
stress, along with the reduction of heart rate, and dP/dt have been 
suggested as potential benefits of celiprolol as preventive therapy 
for vEDS.52 The clinical use of celiprolol as a preventative mea-
sure for the life-threatening arterial dissections and ruptures and 
organ ruptures associated with vEDS has been suggested based 
on the agent’s capacity to reduce heart rate, mean pressure, and 
pulsatile pressure. Thus, celiprolol can decrease the continuous 
and pulsatile mechanical stress on collagen fibers within the 
arterial wall.43,51 In addition, celiprolol is thought to strengthen 
the arterial wall potentially via the upregulation of collagen syn-
thesis. Given the strong associations between β-adrenoceptors 
and transforming growth factor-β (TGFβ) pathways, Ong et 
al43 suggested that β2 stimulation by celiprolol could enhance 
collagen synthesis via the TGFβ pathway. Moreover, Brooke44 
suggested that β-adrenoceptor blockers suppress TGFβ expres-
sion, which could result in decreased matrix turnover, which 
ultimately reduces the continuous mechanical stress on collagen 
fibers within the vascular wall and increases the elasticity of the 
radial artery.
CONCLUSIONS
In a recent publication, Thanawala et al53 recommend against 
grouping all β-adrenoceptor antagonists into 1 class. The authors 
discussed a 3-state model of receptor activation that correlated with 
biased signaling of ligands. This was best represented when review-
ing clinical data that demonstrated that not all β-adrenoceptor antago-
nists were effective in treating congestive heart failure.53 This further 
confirms the idea that classification of β-adrenoceptor antagonists 
should be founded on several factors: affinity, β1-selectivity, partial 
agonist activity, and physicochemical properties.1 On the basis of 
celiprolol’s unique pharmacologic profile, a β1 adrenergic antago-
nist with partial β2 agonist activity, reported β3-agonism, mild α2-
antagonism, lack of membrane-stabilizing or local anesthetic activity, 
vasodilator properties, and the minimal occurrence of typical side 
effects of the β-adrenergic antagonist class (eg, bronchoconstriction, 
depression of left ventricular function, and peripheral vasoconstric-
tion), one may consider labeling celiprolol as a SAM rather than as 
a β-blocker. Moreover, in light of the associations reported between 
β-adrenergic receptors and the TGFβ signaling cascade, investiga-
tion into celiprolol’s therapeutic efficacy via this mechanism is likely 
to further contribute to management of patients with vEDS and per-
haps other rare cardiovascular diseases such as Loeys–Dietz syn-
drome and Marfan syndrome, in which TGFβ is believed to play a 
significant role in disease pathogenesis.43,54
vEDS is a rare genetic connective tissue disorder with life-
threatening complications that include arterial dissections and rup-
tures, and intestinal and uterine ruptures.14 Currently, there are no 
FDA-approved therapies for vEDS in the United States, and phy-
sicians face the challenge of establishing an effective preventative 
treatment plan for their patients.18,55 Given its good tolerability and 
efficacy in a controlled, randomized clinical trial in preventing cata-
strophic vascular events and solid-organ ruptures, celiprolol may rep-
resent an agent with the ability to preemptively reduce the morbidity 
and mortality associated with vEDS. As such, it would represent a 
unique and innovative use of an agent from a class of drugs with a 
well-established track record of efficacy in treating other cardiovas-
cular conditions.
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